BPC-157 vs GHK-Cu compares two popular “healing” peptides that do very different jobs. BPC-157 is a 15-amino-acid peptide studied mostly for tendon, muscle and gut injuries in rats, while GHK-Cu is a three-amino-acid copper peptide used mainly in skincare.[2][4] Neither has proven benefit in a large controlled human trial, and neither is an FDA-approved drug.[11][10]
BPC-157 vs GHK-Cu at a glance
| BPC-157 | GHK-Cu | |
|---|---|---|
| What it is | Synthetic 15-amino-acid peptide based on a stomach protein[2] | Natural copper-binding tripeptide found in human blood[4] |
| Main uses marketed | Tendon, ligament, muscle and gut healing | Skin aging, hair, wound healing |
| Best-studied effect | Blood vessel growth in rats[20] | Collagen production in cell cultures[3] |
| Human trials | 3 small uncontrolled pilots (under 30 people)[2] | A few small topical trials; none of injections[10] |
| Common routes | Injection, capsules | Creams and serums; injections increasingly sold[15] |
| Legal status | Not approved; not a legal supplement[11] | Legal cosmetic ingredient; not an approved drug[12] |
| WADA 2026 | Prohibited (S0)[16] | Not named[16] |
How each one works
BPC-157 was developed in Croatia from a fragment of a gastric juice protein. In lab and animal work it switches on blood-vessel-growth signaling (VEGFR2 and nitric oxide)[20] and raises growth hormone receptors on tendon cells, while lowering inflammatory signals.[1] FDA notes its precise molecular target has not been identified.[11]
GHK-Cu (glycine-histidine-lysine bound to copper, also called copper tripeptide-1) was first isolated from human plasma. In skin cell cultures it stimulated collagen production at very low concentrations.[3] Reviews by its discoverer report that it influences many genes involved in repair and inflammation, but a 2026 analysis noted that much of the literature comes from the same small group of authors.[4][10]
In short: BPC-157 is pitched as an internal repair signal, GHK-Cu as a skin and connective-tissue remodeler.
Evidence quality
BPC-157
A 2025 systematic review of musculoskeletal research found 36 studies, of which 35 were in animals.[1] Human data are limited to three small uncontrolled pilots with fewer than 30 people in total:[2]
- Knee pain: 14 of 16 patients at a Florida clinic reported relief after knee injections, measured by phone survey.[7]
- Bladder pain: 10 of 12 women with interstitial cystitis reported complete relief after one injection, with no control group.[8]
GHK-Cu
GHK-Cu has a handful of human trials, mostly topical, and the published controlled ones are mixed:
- After laser resurfacing: in 13 patients, a GHK-Cu skin regimen did not improve redness, wrinkles or skin quality on objective measures; only patient satisfaction was higher.[5]
- Leg ulcers: in 86 patients with venous ulcers, a 0.4% copper tripeptide cream did no better than placebo, while silver sulfadiazine cream did.[6]
- Anti-wrinkle use: a 2025 review noted a surprising lack of clinical studies.[19]
For injectable GHK-Cu, a 2026 sports medicine primer found no clinical data supporting its use for musculoskeletal conditions.[9]
Results people are looking for
| Goal | BPC-157 | GHK-Cu |
|---|---|---|
| Tendon or ligament injury | Rat data; one uncontrolled knee series[1] | No clinical data[9] |
| Skin wrinkles | Not studied | Small trials, mixed results[5][19] |
| Chronic wounds | Rat burn-wound study only[21] | No benefit over placebo in leg ulcers[6] |
| Gut problems | Croatian enema trials, never fully published[11] | Not studied |
Side effects and safety
- BPC-157: the small human pilots reported no serious side effects but monitored little. FDA has described reports of injection-site reactions and an ER visit for shortness of breath, with causes unclear.[11] Cleveland Clinic calls a possible link to cancer growth a theoretical concern because of its effect on blood vessels.[18]
- GHK-Cu (topical): generally well tolerated as a cosmetic ingredient.
- GHK-Cu (injected): FDA has said injectable GHK-Cu may pose a risk of immune reactions from clumping and impurities, with limited human data.[12] Dermatologists interviewed by NPR in 2026 advised against injecting it.[15]
- Copper load: the NIH sets the adult upper limit for copper at 10 mg a day from food and supplements, based on liver damage at higher intakes; people with Wilson’s disease are at particular risk.[14]
Legal status in 2026
- BPC-157: not approved. FDA staff recommended against allowing it in compounding in July 2026, but advisers reportedly voted 8 to 6 in favor; the vote is not binding.[11][17] Details are in our BPC-157 legal status guide.
- GHK-Cu: legal in cosmetics. FDA removed injectable GHK-Cu from its compounding safety-risk list in April 2026 after the nomination was withdrawn, which is not an approval, and is still evaluating it for non-injectable uses.[12][13]
- Sport: BPC-157 is banned at all times; GHK-Cu is not named on WADA’s 2026 list.[16]
Topical, oral or injected: why the route matters
The way each peptide is used changes the risk picture. GHK-Cu’s track record comes from creams and serums that sit on the skin, and its few positive human results, such as a 2026 eyebrow study, were topical.[10] Injecting it under the skin delivers peptide and copper into the body in a way that has not been studied in people, which is why NPR’s 2026 reporting described the injection trend as running ahead of the science.[15]
BPC-157 is the reverse. It is mostly injected, and it is unusually stable in stomach acid, which is why capsules are also sold. But no oral or injectable product has been developed and validated to pharmaceutical standards, and its half-life in the blood is under 30 minutes.[2] For more, see our guide to oral vs injectable BPC-157.
Can they be combined?
Both appear in multi-peptide blends such as GLOW and KLOW, usually alongside TB-500. No study has tested BPC-157 and GHK-Cu together. For the better-known pairing, see BPC-157 vs TB-500.
Who might consider which? Questions for a clinician
- Is my goal skin appearance (where topical copper peptides are a legal cosmetic option) or an injury (where standard rehab has the best evidence)?
- Would an approved treatment with real trial data do the same job?
- Do I have liver disease, a copper disorder or a history of cancer?
- Am I drug-tested for sport?
The verdict
If the question is skin, topical GHK-Cu is a legal, low-risk cosmetic ingredient with modest and inconsistent evidence. If the question is injury healing, BPC-157 has more animal data but no proof in people, and it is banned in sport. Injecting either one moves you into territory with no human safety data. Related reading: oral vs injectable BPC-157, peptides vs PRP and the healing peptides hub.
This is general information, not medical advice.
